Antibodies that target the PD-1/PD-L1 pathway, including pembrolizumab and nivolumab, have received approval for advanced HNSCC and have shown enhanced outcomes in certain patient populations (1). Here, CD274 is linked to head and neck squamous cell carcinoma.